Epizyme, Inc.

Ipsen SA has posted a decent set of fourth quarter financials, with CEO David Loew touting the French drugmaker's pipeline progress which should result in the launches for four new medicines or new i

Ipsen SA has posted a reasonable set of third quarter financials, including the first sales of its recently approved ultra-rare disorder drug Sohonos, but growth plans for its bile acid modulator, By

In the last couple of years, through a combination of in-licensing and acquisitions, Ipsen SA has added 20 assets to its pipeline across its three focus areas of oncology, rare disease and neuroscie

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Busy Moderna Inks Gene-Editing Pact Wit